- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.05. | BMS brings the buzz around late-stage readouts amid a so-so Q1 | ||
| 01.05. | LEO Pharma to acquire gene therapy company Replay | ||
| 30.04. | Chiesi widens rare disease portfolio with $1.9bn KalVista buyout | ||
| 30.04. | Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy | ||
| 30.04. | Ray Therapeutics receives EMA PRIME status for gene therapy | ||
| 30.04. | Regeneron Q1 2026 net income falls 10% to $727m | ||
| 29.04. | Pfizer protects $6.4bn heart disease blockbuster from generics, for now | ||
| 29.04. | Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact | ||
| 29.04. | Novartis' Q1 sales miss hints at industry's utilisation of M&A remedies | ||
| 29.04. | Arcera and Fosun sign MoU for neuroscience innovation | ||
| 29.04. | Rocket to sell PRV for $180m to advance gene therapy pipeline | ||
| 28.04. | Merck KGaA and Remepy join forces to develop combo drug-digital therapies | ||
| 28.04. | Seaport Therapeutics and Hemab target $180m IPOs as biotech listings accumulate | ||
| 28.04. | BioMarin acquires Amicus Therapeutics for $4.8bn | ||
| 28.04. | FDA approves AstraZeneca's Saphnelo for SLE | ||
| 27.04. | Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics | ||
| 27.04. | Novartis secures pair of regulatory wins for skin disease and malaria treatments | ||
| 27.04. | UK biotech could be bound for recovery, BIA report reveals | ||
| 27.04. | Sun Pharma to acquire Organon for $11.75bn | ||
| 24.04. | Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings | ||
| 24.04. | OZMOSI and Planview partner to enhance pharmaceutical data integration | ||
| 24.04. | Regeneron cuts White House pricing deal, offers new gene therapy for free | ||
| 24.04. | Cumberland to sell drug portfolio to Apotex for $100m | ||
| 23.04. | 500,000 patients' data for sale online after UK Biobank breach | ||
| 23.04. | Sanofi receives FDA approval for Tzield in paediatric diabetes |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.